Life Science Compliance Update

« August 2009 | Main | October 2009 »

37 posts from September 2009

September 30, 2009

Health Care Reform: Senate Finance Committee Rejects Public Option

After hours of debate, the Senate Finance Committee “rejected amendments Tuesday that would add a government-run health-insurance plan to the committee's health-care legislation,” according to the Wall Street Journal. The amendment offered by Senator Rockefeller (D-WV), which would have created a public health-insurance option, was rejected by a 15-8 vote. The Finance Committee’s bill is now the only version of health-care legislation in the House or Senate this year that omits the public health-insurance option.

All Republicans on the panel voted against Mr. Rockefeller's amendment, in addition to five Democrats: Senate Finance Chairman Max Baucus (D-MT), Bill Nelson (D-FL), Kent Conrad (D-ND), Blanche Lincoln (D-AR) and Thomas Carper (D-DE).

Mr. Rockefeller's legislation would create a public option that “would inherit Medicare's network of doctors and hospitals and pay them based on Medicare payment rates for its first two years.”

In response, Senator Schumer (D-NY) offered to create a public plan “that would pay doctors and hospitals at negotiated rates rather than Medicare rates.” This attempt also failed by a 13-10 vote.

Advocates of the public option such as Mr. Rockefeller believe that a public option is necessary “to hold costs down and provide ample competition for private insurers.” The problem with these theories however, is that numerous reports have shown (e.g. CBO on preventive care) that health care reform as large as the public option will cost Americans too much, and will not solve our problems. It will bring a whole new set of problems (e.g. reimbursement rates getting lower), and it will tremendously exaggerate problems that already exist such as shortage of providers, gaps in coverage, and especially fraud, waste and abuse.

While Democrats continue to urge the need for a public option to lower prices by creating competition, Republicans are asserting that such a plan would “expand the federal government's reach and eliminate private insurers.”

Opponents of a public plan note that such an option would "crowd out private insurers with artificially low prices, eventually forcing private insurers to absorb unpaid costs within the U.S. health system and charge their policyholders higher premiums.” Many, like Senator Grassley (R-IA), believe a public option will only lead toward a government-controlled, single-payer health care." It will also force private insurers out of business, which will result in tremendous job loss and economic stress for thousands of families. As of today, the only assurance Democrats or President Obama have offered about a public plan is that it would “compete fairly because it would have to follow the same rules as private insurers.”

The problem with this assertion, as Senator Grassley put it, is that “the federal government will not only be running the plan, it will also be running the market in which it competes with the private plans.” So how exactly does that mean competition would be on a level playing field?

Even the America's Health Insurance trade group noted that “a public health-insurance option would dismantle employer coverage, bankrupt hospitals, and add to the federal deficit," according to spokesman Robert Zirkelbach.

While many advocates hope to see a public option in the bill with bipartisan support, even Chairman Baucus noted such a bill would not gain the 60 votes needed. Instead, he suggested that imposing new regulations on insurers will make up for the difference, such as barring insurers from excluding potential policyholders if they have a pre-existing health condition.

In eliminating the public option, the Senate Finance Bill will increase competition, by devoting “$6 billion to help start up health-insurance co-operatives, which would be non-government entities operating within states.” Although these non-profit cooperatives could provide strong not for profit competition to the private insurers, the Congressional Budget Office has questioned whether the cooperatives would really have much effect.

As the debate today continued, Senator Schumer pressed Senator Grassley about his views on Medicare. In response to questions about his support, Mr. Grassley noted that “Medicare did not pose a threat to the private insurance industry … because it’s not easy to undo … without also hurting a lot of private initiatives that are coupled with it.”

There is the possibility of including a public option when the Senate and House meet for conference proceedings.  

With the debate still to continue, today’s showdown is a mirror of what will take place on the full Senate floor, especially with the New York Times that even Senate Majority Leader Harry Reid “will not include a provision for the public option when he combines the measures coming out of the finance and health committees.”

All of this opposition to a public plan is telling of how inefficient government run health care already is. Since your health-care providers do not want more government run health care programs like Medicare because they already “pay too little for procedures, physician and hospital visits, and equipment,” then ask yourself if you want such an option for your doctor.

FDA Hires IOM to Review Medical Device Approval System

The Food and Drug Administration (FDA) recently issued a press release announcing the commissioning of the Institute of Medicine (IOM) to study the premarket clearance process for medical devices in the U.S.

According to the release, the IOM study will examine the premarket notification program, also called the 510(k) process, for medical devices, and the FDA’s Center for Devices and Radiological Health (CDRH) will convene its own internal working group to evaluate and improve the consistency of FDA decision making in the 510(k) process.

The goals of these evaluations according to Jeffrey Shuren, M.D., acting director of CDRH, is to help “determine how the 510(k) process can be improved to better support FDA’s mission to protect and promote the public health.”

The 510(k) process was established under the Medical Device Amendments of 1976 with two goals:

  • Make safe and effective devices available to consumers
  • Promote innovation in the medical device industry.

The release calls for review of the 510(k) process because “technology and the medical device industry have changed dramatically.” The IOM commission will specifically try to answer two principal questions:

  • Does the current 510(k) process optimally protect patients and promote innovation in support of public health?
  • If not, what legislative, regulatory, or administrative changes are recommended to achieve the goals of the 510(k) process?

The $1.3 million IOM review is slated for completion in 2011. Part of the review will include two public workshops during the next nine months, as well a final report that will be published in March 2011. Dr. Shuren also noted that in addition to this review he has outlined six priorities for CDRH including:

  • Creating an internal task force on the use of science in regulatory decision-making
  • Developing an effective compliance strategy
  • Optimally integrating premarket and postmarket information
  • Increasing transparency in decision-making
  • Establishing clear procedures to resolve differences of opinion.

While it is certainly important for the FDA and CDRH to monitor such changes, it is equally important not to hinder such breakthroughs—often led by collaboration with industry and academia—through burdensome evaluations that scare away scientists and researchers. The criteria IOM should focus on is ensuring that the technological breakthroughs from the medical device and drug industries are kept intact, so that we can keep treating patients and saving lives.   Simply setting up further delays in approvals does not constitute a solution.

For more information about the FDA premarket approval of devices read the GAO report on FDA system for device approval.

FDA Hearing on Internet and Web 2.0


At the beginning of the year the Food and Drug Administration (FDA) sent warning letters to 10 companies concerning advertising on the internet.   Recently the agency announced that they will be hosting a series of hearings on the internet and the web 2.0.  The eventual goal is to come up with a much needed guidance on drug and device advertising on the internet and social media.


FDA's Center for Drug Evaluation and Research (CDER), in collaboration with FDA's Center for Biologics Evaluation and Research (CBER), Center for Veterinary Medicine (CVM), and Center for Devices and Radiological Health (CDRH), recently gave notice of a public hearing it will be holding this November regarding the Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet and Social Media Tools.


The hearing will discuss issues related to the promotion of FDA-regulated medical products (including prescription drugs for humans and animals, prescription biologics, and medical devices) using the Internet and social media tools.


Those members of the public interested in participating can find a list of questions and topics that will be discussed at the hearing from the link listed above.




Interested persons may submit written comments (two copies required) to the Division of Dockets Management to:


Docket No. FDA-2009-N-0441

Division of Dockets Management (HFA-305), Food and Drug Administration 5630 Fishers Lane, rm. 1061, Rockville, MD 20852


Electronic comments should be submitted by going to and using electronic registration and electronic comments. Electronic comments should be identified with Docket No. FDA-2009-N-0441.


Written or electronic comments will be accepted until February 28, 2010.


Dates and Times: The public hearing will be held on November 12 and 13, 2009, from 8 a.m. to 5 p.m. each day.


Location: The public hearing will be held at the National Transportation Safety Board Conference Center, 429 L'Enfant Plaza, SW., Washington, DC 20594, 202-314-6305; Metro: L'Enfant Plaza station on the yellow, green, orange, and blue lines.


The meeting will take up several questions:


  • What types and which online messages, posting and chatter are regulated companies responsible for? And what's not their problem?
  • How do companies currently comply with existing regulations, how do those regulations apply to the internet, what changes need to be made, should they require fair balance in shorter communications?
  • What responsibility does a company have to correct misinformation presented by a third party?    (for example Wikipedia, Yahoo and other websites that provide information free of control of industry)
  • What links are appropriate?  When are links misleading.
  • What reporting structure (to the FDA) should be in place for monitoring websites that include information on safety problems or side effects and the reliability of that information?


To register to attend and/or participate in the meeting, submit written or electronic registration as specified above by close of business on October 9, 2009. Registration is free and will be accepted on a first-come, first-served basis.


If you wish to make an oral presentation at the hearing, you must state your intention on your registration submission. To speak, submit your name, title, business affiliation, addresses, telephone and fax numbers, and e-mail address. Presenters should also identify by number each question they wish to address in their presentation and the approximate time requested. The FDA will determine the amount of time allotted to each presenter and the approximate time that each oral presentation is scheduled to begin. Once FDA notifies registered participants of their scheduled times, presenters should submit to FDA two copies of each presentation to be given


Transcripts of the hearing will be accessible after the hearing at


For further information contact: Jean-Ah Kang, Division of Drug Marketing, Advertising, and Communications, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 3270, Silver Spring, MD, 20993-0002, 301-796-4269, FAX:

301-796-8444, e-mail:



Preview | Powered by FeedBlitz


April 2018
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30